Immunoglobulin E specific for Dermatophagoides farinae allergens (Der f-specific IgE) (Der f-specific IgE)

Immunoglobulin E (IgE) specific for Dermatophagoides farinae (house dust mite) allergens is a specialized class of antibodies central to the pathogenesis of house dust mite allergy. These antibodies are synthesized by B cells and plasma cells in response to Der f proteins, notably Der f 1 and Der f 2 (WHO/IUIS Allergen Nomenclature). Once secreted, they circulate and bind to high-affinity FcεRI receptors on mast cells and basophils, sensitizing these effector cells to the allergen (NCBI, 2023). Upon re-exposure to Der f allergens, the cross-linking of surface-bound IgE triggers degranulation and the release of pro-inflammatory mediators like histamine and cysteinyl leukotrienes (JACI, 2020). This process is the primary driver of clinical symptoms in allergic asthma, allergic rhinitis, and atopic dermatitis. On B cells, membrane-bound IgE (mIgE) facilitates antigen uptake and promotes the differentiation of IgE-producing cells. Therapeutic interventions like omalizumab target the Fc region of free IgE, preventing its binding to FcεRI and subsequently downregulating receptor expression on effector cells (StatPearls, 2023). Allergen-specific immunotherapy (AIT) further modulates this pathway by inducing immune tolerance and shifting the antibody profile from IgE toward protective IgG4 (PubMed, 2021).

Other names

House dust mite-specific IgEAnti-Der f IgEDer f-sIgEDermatophagoides farinae-specific Immunoglobulin E

Drugs targeting Der f-specific IgE primarily work through neutralization or immune modulation. Monoclonal antibodies like omalizumab bind to the Fc region (Cε3 domain) of free IgE, preventing its interaction with the high-affinity FcεRI receptor on mast cells and basophils (NCBI, 2023). This reduction in free IgE leads to a secondary downregulation of FcεRI density on effector cells, raising the threshold for activation. Allergen-specific immunotherapy (AIT) utilizes controlled exposure to Der f extracts to induce regulatory T cells (Tregs) and promote a class switch in B cells from IgE to IgG4, which acts as a "blocking" antibody to intercept allergens before they reach cell-bound IgE (JACI, 2020). Experimental therapies like quilizumab target the M1-prime segment of membrane-bound IgE on B cells to deplete the IgE-switched B cell population (PubMed, 2016).